Life Science Investing uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Life Science Investing uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
Life Science Investing uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
Life Science Investing uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease
Life Science Investing uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in ?-Gal A Enzyme Activity in Patients with Fabry Disease
InMed Pharmaceuticals:Â Innovating Cannabinoid-inspired Medicines, Backed by Real Revenue and Clear Path to Value
Nextech3D.ai Announces CEO Evan Gappelberg Acquires 550,000 Shares of Company Stock In Open Market Buys
